Who founded Model Medicines?

Model Medicines was founded by Daniel Haders, Daniel Haders II, Ph.D, Sean Russell in 2019.

Who are Model Medicines's investors?

Model Medicines's investors include 8VC, Particle, Irving Investors, Nex Cubed.

How much funding has Model Medicines raised?

Model Medicines has disclosed $31.7M raised across 6 rounds.

Where is Model Medicines headquartered?

Model Medicines is headquartered in La Jolla, US.

Model Medicines

La Jolla, US · Founded 2019 · Delaware corporation · 15 employees on LinkedIn · 5 known investors

Find your way into Model Medicines

Paths you didn't know you had: your email and LinkedIn already hold routes to the Model Medicines team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Model Medicines is an AI-powered biotechnology company that uses computation to discover and engineer small molecule drugs targeting disease-driving biological mechanisms. The company has programs in infectious disease, oncology, and inflammation, with compounds in development including a broad-spectrum antiviral and a BRD4 inhibitor.

AI & Machine Learning Biotech Deep Tech Digital Health

Founders & leadership

Model Medicines was founded in 2019 by Daniel Haders, Daniel Haders II, Ph.D, and Sean Russell.

Daniel Haders Co-Founder, Board Director, Executive ChairmanDaniel Haders holds a PhD in Biomedical Engineering and serves as Co-Founder and CEO of Model Medicines, an AI-driven biotechnology company developing small-molecule therapeutics. Previously, he launched a digital health accelerator managing a portfolio of early-stage healthcare companies and served as an operating partner in venture capital advising on digital health investments.

Daniel Haders II, Ph.D Co-Founder, Board Director, Executive ChairmanDaniel Haders II holds a Ph.D. and BS in Biomedical Engineering and previously led a digital health accelerator managing a portfolio of 25+ early-stage healthcare companies and serving as an operating partner in venture capital advising on digital health investments. He is now founder and CEO of Model Medicines, an AI-driven biotechnology company developing small molecule therapeutics.

Sean RussellCo-founder, Chief Operating Officer and Head of Discovery, Research and DevelopmentSean Russell has over 20 years of drug development experience, having overseen more than 20 INDs and 12 NDAs that contributed to the approval of multiple therapies across CNS, infectious disease, women's health, and autoimmune indications. He is Chief Operating Officer at Model Medicines, an AI-powered biotech company developing small molecule drugs through its proprietary GALILEO platform.

Kip QuackenbushMember Board Of Directors2019–2024Kip Quackenbush has held executive leadership roles in enterprise software and SaaS companies including Oracle, Commerce One, Akonix, Red Condor, Edgewave, ProfitLine, Sendio, Accelerate IT Advisors, and Nex Cubed, managing teams and revenue targets across various scales.

Marlon EvansBoard Member2019–2024Marlon Evans has held executive leadership roles spanning higher education, nonprofit organizations, Fortune 500 companies, venture capital, and startups, with over 15 years of experience as a CEO or Executive Director.

Investors · 5

8VClisted by 8VCAustin · $500K – $50M

How we know: 8VC's portfolio page · a partner's Signal profile · prnewswire.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Particlelisted by ParticleHong Kong

Irving InvestorsreportedNew York

How we know: prnewswire.com · Not right? Tell us

Nex CubedreportedLa Jolla

How we know: prnewswire.com · Not right? Tell us

Also in the syndicate · 1

Particle X

Funding

SEC filings, press & company announcements

$31.7M disclosed across 6 rounds · 2020–2026

$4.1MraisedNov 2021 · 2 sources
8VC, Irving Investors, Nex Cubed, Particle X
Source ↗

▶$5.1MraisedOct 2026 · 37 investors · Other

Rule 506(b)